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Background: Cell-mediated immunity is often suppressed in patients with hematological malignancies. Recently,
we found that low T cell receptor (TCR)-CD3 signaling was related to abnormal expression of the negative
regulator of nuclear factor kappa B (NF-κB) A20 in acute myeloid leukemia. To investigate the characteristics of
T cell immunodeficiency in lymphomas, we analyzed the expression features of A20 and its upstream regulating
factor mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) and genes downstream of
NF-κB in patients with different lymphoma subtypes, including T cell non-Hodgkin lymphoma (T-NHL), B cell
non-Hodgkin lymphoma (B-NHL) and NK/T cell lymphoma (NK/T-CL).
Methods: Real-time PCR was used to determine the expression level of the MALT1, MALT-V1 (variant 1), A20 and
NF-κB genes in peripheral blood mononuclear cells (PBMCs) from 24 cases with T-NHL, 19 cases with B-NHL and 16
cases with NK/T-CL, and 31 healthy individuals (HI) served as control.
Results: Significantly lower A20 and NF-κB expression was found in patients with all three lymphoma subtypes
compared with the healthy controls. Moreover, the MALT1 expression level was downregulated in all three
lymphoma subtypes. A significant positive correlation between the expression level of MALT1 and A20, MALT1-V1
and A20, MALT1-V1 and NF-κB, and A20 and NF-κB was found.
Conclusions: An abnormal MALT1-A20-NF-κB expression pattern was found in patients with lymphoma, which may
result a lack of A20 and dysfunctional MALT1 and may be related to lower T cell activation, which is a common
feature in Chinese patients with lymphoma. This finding may at least partially explain the molecular mechanism of
T cell immunodeficiency in lymphomas.
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Lymphoma is a cancer of the immune system, which in-
cludes more than 20 malignant diseases that originate
from B, T or NK/T cells, and occurs via the malignant
proliferation of lymphocyte clones [1]. The development,
maintenance, and progression of malignant lymph-
omas mechanistically depend on deregulation of cellular* Correspondence: liwy1206@163.com; yangqiuli@hotmail.com
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unless otherwise stated.pathways that control differentiation, proliferation, or
apoptosis in lymphocytes [2]. Moreover, immune func-
tion disorders are associated with a risk for malignant
transformation [1]. As previously reported, immune defi-
ciency is one of the best characterized and strongest
known risk factors for lymphoma, particularly non-
Hodgkin Lymphoma (NHL). The incidence of lymphoma
in people with congenital or acquired immune deficiency
is 50 or more times higher than that in the healthy popu-
lation [1,3]. For example, patients with weakened im-
mune systems such as those with an HIV infection or
from certain drugs or medications have a higher inci-
dence of lymphoma [4,5]. Recently, the nuclear factor-κBtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of lymphoma samples and healthy
control
Diagnosis n Gender Age (year) Stage
Male Female Median Range I II III IV
T-NHL 24 12 12 42 12-78 9 1 1 13
B-NHL 19 12 7 56 21-78 3 3 5 8
NK/T-CL 16 13 3 39 13-74 3 2 1 10
HL 31 17 14 38 25-72
Note: T-NHL T cell non-Hodgkin lymphoma, B-NHL B cell non-Hodgkin lymphoma,
NK/T-CL NK/T cell lymphoma, HI healthy individuals
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tightly regulated signaling cascade that mediates the de-
velopment, activation, and survival of normal lympho-
cytes for regulated immune responses [2]. Moreover,
many of the oncogenic mediators involved in the path-
ology of lymphoma are regulated by NF-κB [6]. Abnor-
mal NF-κB activation occurs during many pathological
conditions including different abnormalities of the im-
mune system and malignancies.
The CBM complex, including CARMA1 (caspase-
recruitment domain (CARD)–containing membrane-
associated guanylate kinase protein 1, also called CARD11),
BCL10 (B-cell lymphoma 10) and MALT1 (paracaspase
mucosa-associated lymphoid tissue lymphoma transloca-
tion gene 1), is crucial for TCR–induced NF-κB and T cell
activation [7-10]. The CBM pathway is pathologically
altered in several lymphoma subtypes, such as activated
B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL).
The CBM complex mediates activation of the inhibitor of
NF-κB (IκB) kinase complex (IKK) by ubiquitylation and
phosphorylation events that depend on TRAF6 and
TAK1, respectively. The IKK-mediated phosphorylation
of IκBα targets the inhibitor for proteasomal degradation
and allows the nuclear translocation of NF-κB [10,11].
Studies in MALT1-deficient mice have demonstrated an
essential role for MALT1 in TCR- and BCR-mediated
functions [10,11].
The intracellular ubiquitin-editing protein A20 (also
known as tumor necrosis factor alpha-induced protein 3,
TNFAIP3) is a key player in the negative feedback regu-
lation of NF-κB signaling [12-14]. A20 was identified as
a MALT1 substrate, and MALT1 can cleave A20 at ar-
ginine 439 to impair its NF-κB inhibitory function, thus
emphasizing the importance of the MALT1 proteolytic
activity in the ‘fine tuning’ of T cell antigen receptor sig-
naling [7,11]. Subsequent studies demonstrated that A20
overexpression inhibits NF-κB activation in response to
different stimuli [15,16]. The cloning and characterization
of the A20 promoter revealed the presence of two NF-κB
DNA binding elements, which are recognition sequences
for NF-κB transcription factors. It was also found that mul-
tiple NF-κB activating stimuli induce A20 expression via
NF-κB sites in the A20 promoter [17]. Additionally, recent
genome-wide association studies have demonstrated a
strong link between A20 polymorphisms and a range of
chronic inflammatory disorders including autoimmune dis-
eases, such as systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA) [14]. SLE and RA are associated
with a significantly increased risk for lymphoma, particu-
larly MALT lymphoma [13,14]. Moreover, A20 dysfunction
by deletion or mutation has been identified in numerous
lymphocytic malignancies. The A20 mutations identi-
fied in lymphoma, which are distributed throughout the
gene, affect the ovarian tumour (OTU), ZnF and linkerregions in DLBCL, mantle cell lymphoma (MCL), mucosa-
associated lymphoid tissue (MALT), classic Hodgkin’s
lymphoma (cHL), marginal zone lymphoma (MZL) and
primary mediastinal B cell lymphoma (PMBL) [5].
The etiology of lymphoma remains to be understood;
however, both aberrant NF-κB activation and a weakened
immune system can promote the malignant transform-
ation of lymphocytes. In contrast, cell-mediated immunity
is often suppressed in patients with lymphomas and may
be related to disease progression. Such immune dysfunc-
tion may be due to disorders in thymic output function
and T cell proliferation and activation [18-20], and their
molecular mechanism remains unclear. Few studies have
focused on the expression characteristics of A20, its
regulatory factor MALT1 and NF-κB in patients with
lymphomas and evaluated immune function in patients.
In this study, we analyzed the expression level of all
three genes in samples from Chinese patients with T cell
NHL (T-NHL), B cell NHL (B-NHL), and NK/T cell
lymphoma (NK/T-CL) to further understand the role of




Fifty-nine cases with lymphomas (37 males and 22 fe-
males with a median age of 48 years and a range of 12–
78 years), including T-NHL (24 cases), B-NHL (19 cases)
and NK/T-CL (16 cases), were selected for this study.
Thirty-one healthy individuals (HI) served as control.
Characteristics of lymphoma samples and healthy con-
trol were summarized in Table 1. All of the procedures
in this study were conducted according to the guidelines
of the Medical Ethics committee of the Health Bureau of
Guangdong province, China.
Peripheral blood samples were collected by heparin
anticoagulation, and peripheral blood mononuclear cells
(PBMCs) were isolated using the Ficoll–Hypaque gradient
centrifugation method. The percentage of CD3 + cells in
PBMCs was found around 70%. RNA extraction and
cDNA synthesis were performed according to the manu-
facturer’s instructions.
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The sequences of primers used for MALT1, A20 and
NF-κB gene amplification are listed in Table 2. There
are two variants of the MALT1 gene, MALT1-V1 and
MALT1-V2, and the latter contains a 33 bp deletion
located between exons 6 and 8. To amplify the two
MALT1 transcript variants, the MALT-V1-for and MALT-
V1-rev primer pair was designed for MALT1-V1 amplifica-
tion to amplify the region that is missing in MALT1-V2,
and the MALT1-for and MALT1-rev primer pair was de-
signed to amplify the conserved region, which is found in
both variants [21].
The expression level of the A20, MALT1, MALT1-V1,
NF-κB and β2-microglobulin (β2M) genes was deter-
mined by SYBR Green I real-time PCR. Briefly, PCR was
performed in a 20 μl volume with approximately 1 μl of
cDNA, 0.5 μM of each primer pair, 9 μl of 2.5 × Real
Master Mix (Tiangen Biotech (Beijing) Co. Ltd., Beijing,
China) and 9 μl of dH2O. After initial denaturation at
95°C for 15 minutes, 45 cycles of the following proced-
ure was performed: 30 seconds at 95°C and 40 seconds
at 60°C. The plate was read immediately after the 60°C
step using an MJ Research DNA Engine Opticon 2 PCR
cycler (Bio-Rad, Hercules, CA, USA). The relative amount
of the genes of interest and β2M reference gene was mea-
sured in two independent assays. The specific, amplified
PCR products were analyzed by melting curve analysis.
The data are presented as the relative expression of the
genes of interest compared with the internal control gene
as determined by the 2(-△CT) method [22]. In addition, to
analyze the MALT1-V1 expression characteristics, we cal-
culated the MALT1-V1 expression ratio as MALT1-V1/
MALT1 x 100%.
Statistical analysis
Two independent-samples Wilcoxon tests were per-
formed to compare the median expression level for











β2M Rev 5′-CATCCAATCCAAATGCGGCA-3′NK/T-CL and the control group. Spearman correlation
and linear regression analyses were used to determine the
association between different genes in different groups. A
P <0.05 was considered statistically significant [20].
Results and discussions
Like many cancers and leukemias, patients with lymph-
oma have cell-mediated immune dysfunction [23]. Such
T cell immunodeficiency may at least be partially related
to low T cell receptor (TCR)-CD3 signaling [24,25]. Re-
cently, we found abnormal expression of MALT1, A20,
and NF-κB genes, which may be related to T cell im-
munodeficiency, in T cells from patients with acute mye-
loid leukemia (AML) [21]. In this study, we analyzed the
feature of gene expression pattern in PBMCs from
lymphoma samples, unlike leukemia samples, in which
the most cells in PBMCs are leukemia cells, in this case,
T cells must be sorted from PBMCs [21], while the high
percentage of CD3 + T cells in PBMCs is thought that
could be represented the characteristics of T cells spe-
cially discussing the T cell related pathways. In this study,
we analyzed the expression of A20 in 59 patients with
different lymphoma subtypes (T-NHL, B-NHL and NK/
T-CL), and a significantly lower A20 expression level
(median: 2.967) was found in all lymphoma samples com-
pared with those in healthy individuals (median: 31.754,
P < 0.001). Moreover, there was also a significantly lower
A20 expression level in each T-NHL, B-NHL and NK/
T-CL sample (median: 2.403, 2.816, and 4.183, respectively)
compared with those from the healthy group (P < 0.001 for
all comparisons) (Figure 1A). These results are similar to a
previous finding in AML [21]. It was suggested that the de-
creased A20 in AML may be due to activation of a subset
of T cells, which is thought to be a specific response to
AML cells, and the presence of clonally expanded T cells
in AML and other leukemias may support this hypothesis
[21,26-29]. In this study, the lower A20 expression may be






Figure 1 The A20 (A) and NF-κB (B) expression level in patients with T-NHL, B-NHL and NK/T lymphoma and healthy individuals.
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demonstrating TCR subfamily T cell proliferation may also
support these results [18]. Moreover, A20-deficient mice
have high oncogenic risk [6,12]. Further follow up of the
association between the expression characteristics of A20
and disease progression is needed.
It is well known that NF-κB overexpression plays a key
role in the development of lymphocytic malignant cells
[3,23] and lymphocytes, which mediate inflammation
[30]. However, little is known about the expression char-
acteristics of NF-κB in normal lymphocytes from pa-
tients with lymphocytic malignancies who have T cell
immunodeficiency. Interestingly, in this study, we found
that the NF-κB expression level in PBMC samples from
patients with T-NHL, B-NHL and NK/T-CL (median:
0.584, 0.484, and 0.584, respectively) was decreased. Sig-
nificantly lower NF-κB expression was found in patients
with T-NHL (P = 0.021), B-NHL (P = 0.047) and NK/T-CL
(P = 0.018) in comparison with healthy individuals (median:
0.962) (Figure 1B). This result may further suggest lower
lymphocyte activation in lymphoma patients, and it ap-
pears that lower lymphocyte activation may be in all of
three type lymphomas. However, this result is inconsistent
with the finding of lower A20 expression in samples from
the same lymphoma patients. Because A20 inhibits NF-κB,
lower expression of this protein may reduce its NF-κB in-
hibitory effects, and NF-κB may be upregulated [2,31]. This
phenomenon may exist for two different reasons. First,
there is significantly lower lymphocyte activation, particu-
larly in T cells in lymphoma patients, even when A20 is
downregulated, and these cells may be incapable of upreg-
ulating the expression of NF-κB; second, it may be due to
the abnormal expression of a different NF-κB regulator be-
cause NF-κB is affected by numerous regulatory factors e.
g., MALT1 [6,11]. Moreover, MALT1 is an upstream A20
pathway factor that cleaves A20 at arginine 439 and im-
pairs its NF-κB inhibitory function [32].
To characterize the relationship between MALT1, A20
and NF-κB, we examined the MALT1 expression level.As expected, the MALT1 expression level was signifi-
cantly downregulated in patients with T-NHL (median:
0.186) (P < 0.001), B-NHL (median: 0.177) (P < 0.001)
and NK/T-CL (median: 0.217) (P < 0.001) compared with
healthy individuals (median: 2.105) (Figure 2A). Because
MALT1 is a positive regulatory factor of NF-κB, its lower
protein expression may result in the downregulation of
NF-κB, which is further supported by the finding of a
lower NF-κB level in patients with lymphoma. However,
this result appears to be inconsistent with the lower ex-
pression level of A20, which was identified as a MALT1
substrate and could be cleaved by MALT1 [7]. This find-
ing is similar to phenomena in T cells in AML patients,
which may indicate that there is more than one A20
regulator. For example, there are two MALT1 variants,
MALT1-V1 and MATL1-V2, and little is known about
the functional difference between the variants. Our previ-
ous study found that the MALT1-V1 expression level
was significantly higher in T cells from AML patients
compared with healthy controls, while the MALT1-V2
expression level was downregulated [21]. In this study,
we also analyzed the expression level of the MALT1 vari-
ants. In contrast with the finding in T cells from AML
patients, a significantly lower MALT1-V1 expression
level was detected in patients with T-NHL, B-NHL and
NK/T-CL (median: 0.023, 0.015, and 0.024, respectively)
compared with healthy controls (median: 0.227, P < 0.001
for all comparisons) (Figure 2B). Because we could not
directly amplify MALT1-V2, which has a 33 bp deletion,
the MALT1-V2 expression level could only be indirectly
calculated by the relative expression of MALT1-V1/total
MALT1 [21], and there was no significant difference
in the MALT1-V1/total MALT1 ratio between patients
with T-NHL, B-NHL and NK/T-CL and healthy controls
(median: 12.46, 11.54, and 8.87%, respectively, vs. 12.63%),
implying that the MALT1-V2 expression level was also
downregulated in T-NHL, B-NHL and NK/T-CL. There
are no previous reports describing the expression pat-
tern, distribution, or different biological functions of the
Figure 2 The expression level of MALT1 (A) and MALT1-V1 (B) in patients with T-NHL, B-NHL and NK/T lymphoma and
healthy individuals.
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that described the change in the expression pattern of
MALT1 variants in T cells from patients with AML [21].
In this study, we found that the expression ration of
MALT1-V1 in total MALT1 was14.32 ± 13.21% (median:
11.54%) in lymphoma group, while 12.95 ± 7.10% (median:
12.63%) in healthy group, indicating the common fea-
ture that expression levels of MALT1-V1 was low than
MALT1-V2 in PBMCs from all samples. The different bio-
logical functions of both MALT1 variants is needed further
investigation.
Overall, either MALI1-V1 or MALT1-V2 was decreased
in lymphomas. Thus, our finding of lower MALT1 ex-
pression may imply a loss of control of T cell activation
and even progression toward immune deficiency in lymph-
oma patients. We further analyzed the correlation between
the MALT1 and A20 expression level. In general, A20 is
cleaved by MALT1; thus, the expression level of MALI1-
V1 and MALT1-V2 should be negatively correlated with
the A20 and MALT1 expression pattern [32]. However, we
found a positive correlation between MALT1 and A20
(rs = 0.449, P < 0.001) (Figure 3A) and MALT1-V1 and
A20 (rs = 0.295, P = 0.023) in 60 lymphoma patients. ThisFigure 3 Correlation between the gene expression levels of MALT1 and
with T-NHL, B-NHL and NK/T lymphoma.result implied the abnormal regulation of MALT1 and A20.
Moreover, a positive correlation was found between MALT1
and NF-κB (rs = 0.525, P < 0.001) (Figure 3B) and A20
and NF-κB (rs = 0.390, P = 0.002) (Figure 3C), indicating
that MALT1, A20, and NF-κB lost their normal expres-
sion pattern at the molecular level and may be more
complex in their manner of regulation in lymphoma. Fur-
ther investigation is needed to characterize the upstream
pathway regulators of A20 in addition to MALT1.
In conclusion, we characterized, for the first time, the
alternative expression pattern of MALT1, A20 and NF-
κB, which may be related to abnormal T cell activation
in lymphomas. A lack of A20 and dysfunctional MALT1,
which results in lower T cell activation, are common
characteristics in Chinese patients with T-NHL, B-NHL
and NK/T-CL, and this combination may at least partially
explain the molecular mechanisms involved in T cell im-
munodeficiency in lymphomas. These findings may help
provide new data to consider for target immune regu-
lation in lymphoma. However, further investigation is
needed to follow up on patients with different MALT1-
A20-NF-κB expression patterns and their association with
cancer development.A20 (A), MALT1 and NF-κB (B) and A20 and NF-κB (C) in patients
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